Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5NET 2Thoracic 1

Conditions

Glioblastoma 264Glioma 109Brain Neoplasms 104Gliosarcoma 85Central Nervous System Neoplasms 64Astrocytoma 61Melanoma 46Oligodendroglioma 44Neuroblastoma 28Recurrence 22Neoplasm Metastasis 18Neoplasms 16Medulloblastoma 16Ependymoma 16Sarcoma, Ewing 13Lymphoma 13Sarcoma 12Rhabdomyosarcoma 11Neuroendocrine Tumors 11Lung Neoplasms 11Diffuse Intrinsic Pontine Glioma 10Small Cell Lung Carcinoma 9Neuroectodermal Tumors, Primitive 7Colorectal Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Osteosarcoma 6Pinealoma 5Optic Nerve Glioma 5Choroid Plexus Neoplasms 5Carcinoma, Non-Small-Cell Lung 5

Interventions

Everolimus 7Nivolumab 6Cisplatin 6Temozolomide 5Bevacizumab 5lutetium Lu 177 dotatate 4Fluorouracil 4Carboplatin 4pembrolizumab 3avelumab 3atezolizumab 3Irinotecan 3Ipilimumab 3Etoposide 3Capecitabine 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2Immunoglobulin G 2IFL protocol 2Fluorodeoxyglucose F18 2Drug Therapy 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Neuroendocrine × Temozolomide × Clear all
NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
55 enrolled
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated
53 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT03079440 2022-12-06

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Asan Medical Center

Phase 2 Completed
31 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04122911 2020-10-26

TENEC

National Cancer Institute, Naples

Phase 2 Completed
25 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT02248012 2019-12-19

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Haukeland University Hospital

Phase 2 Completed
38 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡